Resverlogix Corp.

News Releases

Sign up for news alerts

2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
Resverlogix Randomizes First Patient in Taiwan/China Portion of the Phase 3 BETonMACE Clinical Trial
Resverlogix Announces Fourth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone
Resverlogix Comments on TSX Trader Notes
Resverlogix Closes $10 Million of Equity Subscriptions
Resverlogix to Raise Up To $10 Million
Resverlogix Announces Overnight Marketed Equity Offering
Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2017
Resverlogix To Host Epigenetics Focused Symposium At The ERA-EDTA Congress in Madrid, Spain
Resverlogix Receives Approval From Health Canada To Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone
Recent Publication and Patent Application Referencing Apabetalone Support its Continued Development and Success
Resverlogix Receives Approval From The FDA Cardiovascular and Renal Division To Proceed With A Requested Apabetalone Clinical Trial
Resverlogix Announces Third Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone and Provides an Update on Corporate Activities
Resverlogix Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office
Resverlogix Reports Positive FDA Type B Meeting on Design Issues Relating to a Proposed Phase 2a Kidney Dialysis Trial
Resverlogix Highlights Unique Properties of Apabetalone in Both a Rare Muscular Dystrophy (FSHD) and Neurodegenerative Eye Disease
Resverlogix Provides Groundbreaking Results in Patients with Severe Kidney Impairments
Resverlogix Announces Presentation at 9th Annual Biotech Showcase Conference in San Francisco, CA